Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial

被引：6
|
作者：
Baize, N. [1 ]
Monnet, I. [2 ]
Greillier, L. [3 ]
Geier, M. [4 ]
Lena, H. [5 ]
Janicot, H. [6 ]
Vergnenegre, A. [7 ]
Crequit, J. [8 ]
Lamy, R. [9 ]
Auliac, J. B. [10 ]
Le Treut, J. [11 ]
Le Caer, H. [12 ]
Gervais, R. [13 ]
Dansin, E. [14 ]
Madroszyk, A. [15 ]
Renault, P. [16 ]
Legarff, G. [17 ]
Schott, R. [18 ]
Saulnier, P. [1 ]
Chouaid, C. [2 ]
机构：
[1] CHU Angers, Angers, France
[2] Chi Creteil, Pneumol, Creteil, France
[3] Ap Marseille, Serv Oncol Multidisciplinaire & Innovat Therapeut, Marseille, France
[4] CHU Brest, Inst Cancerol & Hematol, Brest, France
[5] CHU Rennes, Serv Pneumol, Rennes, France
[6] Hop Montpied, CHU, Clermont Ferrand, France
[7] CHU Limoges, Limoges, France
[8] Ch Beauvais, Beauvais, France
[9] Ch Bretagen Sud, Lorient, France
[10] Ctr Hosp F Quesnay, Mantes La Jolie, France
[11] Ctr Hosp Pays Aix, Aix En Provence, France
[12] Ctr Hosp St Brieuc, St Brieuc, France
[13] Ctr Francois Baclesse, Caen, France
[14] Ctr Oscar Lambret, Lille, France
[15] Inst Paoli Calmette, Marseille, France
[16] Ch Pau, Pau, France
[17] Ctr Hosp St Brieux, St Brieux, France
[18] Clcc Paul Strauss, Strasbourg, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Small Cell Lun Cancer; second line; phase; 3; trial;
D O I：
10.1016/j.jtho.2019.08.490
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA15.02
引用
收藏
页码：S246 / S246
页数：1
相关论文
共 50 条
  • [21] Randomized phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer.
    Sehouli, J
    Sommer, H
    Klare, P
    Stauch, M
    Zeimet, A
    Paulenz, A
    Renziehausen, K
    Keil, E
    Lichtenegger, W
    Oskay-Ozcelik, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 483S - 483S
  • [22] The role of topotecan in treating small cell lung cancer: second-line treatment
    von Pawel, J
    LUNG CANCER, 2003, 41 : S3 - S8
  • [23] Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
    Eckardt, John R.
    von Pawel, Joachim
    Pujol, Jean-Louis
    Papai, Zsolt
    Quoix, Elisabeth
    Ardizzoni, Andrea
    Poulin, Ruth
    Preston, Alaknanda J.
    Dane, Graham
    Ross, Graham
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 2086 - 2092
  • [24] Outcomes of Small Cell Lung Cancer Patients Treated With Cisplatin-Etoposide Versus Carboplatin-Etoposide
    Karam, Irene
    Jiang, Shi Yuan
    Khaira, Mandip
    Lee, Christopher W.
    Schellenberg, Devin
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (01): : 51 - 54
  • [25] Topotecan in Second-Line Treatment of Small-Cell Lung Cancer -How it Works in Our Daily Clinical Practice?
    Lourenco Moreira Faria, Ana Luisa
    Bravo, Emilio Macias
    Silva Soares Rocha, Marta Alexandra
    Azevedo Rocha, Isabel Maria
    Pequeno Coelho, Ana Luisa
    Ferreira Araujo, Antonio Manuel
    CURRENT DRUG SAFETY, 2010, 5 (02) : 114 - 117
  • [26] Second-line therapy for small-cell lung cancer
    Schmittel, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (04) : 631 - 637
  • [27] Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer
    Chen, Gigi
    Huynh, Minh
    Fehrenbacher, Lou
    West, Howard
    Lara, Primo N., Jr.
    Yavorkovsky, Leonid L.
    Russin, Michael
    Goldstein, Desiree
    Gandara, David
    Lau, Derick
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1401 - 1404
  • [28] Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review
    Futoshi Ushijima
    Tetsunari Hase
    Yuki Yamashita
    Hangsoo Kim
    Tomoya Shimokata
    Chiaki Kondo
    Tomonori Sato
    Tomoya Baba
    Shohei Watanabe
    Keisuke Futamura
    Yuichi Ando
    Masashi Mizuno
    Makoto Ishii
    International Cancer Conference Journal, 2024, 13 : 88 - 92
  • [29] Paclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin-etoposide: A multicenter phase II study.
    Joos, G
    Schallier, D
    Pinson, P
    Sterckx, M
    Van Meerbeeck, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 668S - 668S
  • [30] Chemoradiation with Cisplatin-Etoposide versus Carboplatin-Etoposide in Limited-Stage Small Cell Lung Cancer
    Pellini, B.
    Hasan, S.
    Samson, P.
    Earland, N.
    Ward, J.
    Waqar, S.
    Baggstrom, M.
    Robinson, C. G.
    Govindan, R.
    Devarakonda, S.
    Morgensztern, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S511 - S511
12345